• Subscribe
  • Newsfeed
  • About
  • Jobs
AI Search
Announce News

Alchemab Therapeutics: Venture Capital Funding History

Alchemab Therapeutics

To add a bio or update company history, please click update information.

News from Alchemab Therapeutics

    Alchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseasesAlchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases
    Alchemab Therapeutics
    9 Jul 2026

    Alchemab Therapeutics secures £25m Series A extension from British Business Bank to scale antibody drug discovery pipeline for hard-to-treat diseases

    Alchemab Therapeutics is a clinical-stage biotechnology company that uncovers protective antibodies from disease-resilient individuals to discover and develop novel therapeutics. Its Resiliome platform combines a large human antibody database with AI-derived algorithms and lab validation to identify antibodies that protect against hard-to-treat diseases.

    Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platformAlchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform
    Alchemab Therapeutics
    9 Sept 2025

    Alchemab Therapeutics raises £24m Series A extension led by Ono Venture Investment to advance AI-enabled antibody platform

    Alchemab identifies naturally occurring protective antibodies using AI and patient data, developing new therapies based on disease resilience rather than traditional target discovery.

Alchemab Therapeutics
  • Life Sciences
  • Cambridge, United Kingdom
  • £49m
  • alchemab.com
  • Update Information

More venture news

  • Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
    Oyster Therapeutics
    13 Nov 2026

    Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases

    Series ALife Sciences
  • Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours
    Neobe Therapeutics
    10 Nov 2026

    Neobe lands a £5m seed round led by ARC Ventures to deliver cancer drugs directly into solid tumours

    SeedLife Sciences
  • PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases
    PhaSER Biomedical
    9 Nov 2026

    PhaSER Biomedical secures a £2m grant from Gates Foundation to discover new treatments for neglected diseases

    GrantLife Sciences

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn